239 related articles for article (PubMed ID: 21840673)
1. In vitro synergisms obtained by amphotericin B and voriconazole associated with non-antifungal agents against Fusarium spp.
Venturini TP; Rossato L; Spader TB; Tronco-Alves GR; Azevedo MI; Weiler CB; Santurio JM; Alves SH
Diagn Microbiol Infect Dis; 2011 Oct; 71(2):126-30. PubMed ID: 21840673
[TBL] [Abstract][Full Text] [Related]
2. In vitro interactions of antifungal agents against clinical isolates of Fusarium spp.
Córdoba S; Rodero L; Vivot W; Abrantes R; Davel G; Vitale RG
Int J Antimicrob Agents; 2008 Feb; 31(2):171-4. PubMed ID: 18054469
[TBL] [Abstract][Full Text] [Related]
3. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.
Espinel-Ingroff A
J Clin Microbiol; 2001 Mar; 39(3):954-8. PubMed ID: 11230410
[TBL] [Abstract][Full Text] [Related]
4. In vitro interactions between amphotericin B and other antifungal agents and rifampin against Fusarium spp.
Spader TB; Venturini TP; Cavalheiro AS; Mahl CD; Mario DN; Lara VM; Santurio J; Alves SH
Mycoses; 2011 Mar; 54(2):131-6. PubMed ID: 19780977
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
Kaya AD; Kiraz N
Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
[TBL] [Abstract][Full Text] [Related]
6. Synergysm of voriconazole or itraconazole with other antifungal agents against species of Fusarium.
Spader TB; Venturini TP; Rossato L; Denardi LB; Cavalheiro PB; Botton SA; Santurio JM; Alves SH
Rev Iberoam Micol; 2013; 30(3):200-4. PubMed ID: 23402831
[TBL] [Abstract][Full Text] [Related]
7. In vitro evaluation of combination antifungal activity against Fusarium species isolated from ocular tissues of keratomycosis patients.
Li L; Wang Z; Li R; Luo S; Sun X
Am J Ophthalmol; 2008 Nov; 146(5):724-8. PubMed ID: 18707669
[TBL] [Abstract][Full Text] [Related]
8. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp.
Philip A; Odabasi Z; Rodriguez J; Paetznick VL; Chen E; Rex JH; Ostrosky-Zeichner L
Antimicrob Agents Chemother; 2005 Aug; 49(8):3572-4. PubMed ID: 16048988
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity (MIC and MFC) of voriconazole, amphotericin B, and itraconazole against 192 filamentous fungi: the GISIA-2 study.
Morace G; Drago M; Scaltrito MM; Conti S; Fanti F; Polonelli L;
J Chemother; 2007 Oct; 19(5):508-13. PubMed ID: 18073149
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Sensititre YeastOne with the NCCLS M38-A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.
Guinea J; Peláez T; Alcalá L; Bouza E
Diagn Microbiol Infect Dis; 2006 Sep; 56(1):53-5. PubMed ID: 16650953
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity and synergism of amphotericin B, azoles and cationic antimicrobials against the emerging pathogen Trichoderma spp.
Kratzer C; Tobudic S; Schmoll M; Graninger W; Georgopoulos A
J Antimicrob Chemother; 2006 Nov; 58(5):1058-61. PubMed ID: 16987867
[TBL] [Abstract][Full Text] [Related]
12. In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp.
Lewis RE; Wiederhold NP; Klepser ME
Antimicrob Agents Chemother; 2005 Mar; 49(3):945-51. PubMed ID: 15728887
[TBL] [Abstract][Full Text] [Related]
13. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies.
Espinel-Ingroff A; Johnson E; Hockey H; Troke P
J Antimicrob Chemother; 2008 Mar; 61(3):616-20. PubMed ID: 18222957
[TBL] [Abstract][Full Text] [Related]
14. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
[TBL] [Abstract][Full Text] [Related]
15. Correlation between the E test and the CLSI M-38 A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.
Guinea J; Peláez T; Alcalá L; Bouza E
Diagn Microbiol Infect Dis; 2007 Mar; 57(3):273-6. PubMed ID: 17141455
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of miltefosine as a single agent and in combination with voriconazole or posaconazole against uncommon filamentous fungal pathogens.
Biswas C; Sorrell TC; Djordjevic JT; Zuo X; Jolliffe KA; Chen SC
J Antimicrob Chemother; 2013 Dec; 68(12):2842-6. PubMed ID: 23861311
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis.
Bueno JG; Martinez C; Zapata B; Sanclemente G; Gallego M; Mesa AC
Clin Exp Dermatol; 2010 Aug; 35(6):658-63. PubMed ID: 19874354
[TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibility of filamentous fungi to itraconazole, voriconazole and posaconazole by Clinical and Laboratory Standards Institute reference method and E-test.
Kondori N; Svensson E; Mattsby-Baltzer I
Mycoses; 2011 Sep; 54(5):e318-22. PubMed ID: 20557462
[TBL] [Abstract][Full Text] [Related]
19. Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M 38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole.
Espinel-Ingroff A; Fothergill A; Ghannoum M; Manavathu E; Ostrosky-Zeichner L; Pfaller M; Rinaldi M; Schell W; Walsh T
J Clin Microbiol; 2005 Oct; 43(10):5243-6. PubMed ID: 16207990
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.
Arikan S; Sancak B; Alp S; Hascelik G; McNicholas P
Med Mycol; 2008 Sep; 46(6):567-73. PubMed ID: 19180726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
